Logo image of XERS

XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Fundamental Analysis

NASDAQ:XERS - Nasdaq - US98422E1038 - Common Stock - Currency: USD

3.75  -0.22 (-5.54%)

After market: 3.75 0 (0%)

Fundamental Rating

2

XERS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. XERS may be in some trouble as it scores bad on both profitability and health. XERS is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XERS had negative earnings in the past year.
XERS had a negative operating cash flow in the past year.
In the past 5 years XERS always reported negative net income.
In the past 5 years XERS always reported negative operating cash flow.
XERS Yearly Net Income VS EBIT VS OCF VS FCFXERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a decent Return On Assets value of -19.66%, XERS is doing good in the industry, outperforming 62.16% of the companies in the same industry.
Industry RankSector Rank
ROA -19.66%
ROE N/A
ROIC N/A
ROA(3y)-29.03%
ROA(5y)-51.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XERS Yearly ROA, ROE, ROICXERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500

1.3 Margins

XERS has a better Gross Margin (81.36%) than 85.95% of its industry peers.
XERS's Gross Margin has declined in the last couple of years.
XERS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.89%
GM growth 5Y-2.98%
XERS Yearly Profit, Operating, Gross MarginsXERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

XERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XERS has been increased compared to 1 year ago.
The number of shares outstanding for XERS has been increased compared to 5 years ago.
Compared to 1 year ago, XERS has a worse debt to assets ratio.
XERS Yearly Shares OutstandingXERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
XERS Yearly Total Debt VS Total AssetsXERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

XERS has an Altman-Z score of -1.56. This is a bad value and indicates that XERS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.56, XERS perfoms like the industry average, outperforming 45.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.56
ROIC/WACCN/A
WACC11.29%
XERS Yearly LT Debt VS Equity VS FCFXERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 1.79 indicates that XERS should not have too much problems paying its short term obligations.
The Current ratio of XERS (1.79) is worse than 64.86% of its industry peers.
A Quick Ratio of 1.29 indicates that XERS should not have too much problems paying its short term obligations.
XERS's Quick ratio of 1.29 is on the low side compared to the rest of the industry. XERS is outperformed by 74.05% of its industry peers.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.29
XERS Yearly Current Assets VS Current LiabilitesXERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for XERS have decreased by 0.00% in the last year.
Looking at the last year, XERS shows a very strong growth in Revenue. The Revenue has grown by 22.72%.
XERS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 130.85% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.22%
Revenue 1Y (TTM)22.72%
Revenue growth 3Y100.29%
Revenue growth 5Y130.85%
Sales Q2Q%12.31%

3.2 Future

XERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.94% yearly.
XERS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.36% yearly.
EPS Next Y8.2%
EPS Next 2Y23.14%
EPS Next 3Y28.69%
EPS Next 5Y27.94%
Revenue Next Year23.63%
Revenue Next 2Y21.44%
Revenue Next 3Y20.74%
Revenue Next 5Y20.36%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
XERS Yearly Revenue VS EstimatesXERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
XERS Yearly EPS VS EstimatesXERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XERS. In the last year negative earnings were reported.
Also next year XERS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XERS Price Earnings VS Forward Price EarningsXERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XERS Per share dataXERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

XERS's earnings are expected to grow with 28.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.14%
EPS Next 3Y28.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XERS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XERIS BIOPHARMA HOLDINGS INC

NASDAQ:XERS (2/21/2025, 8:00:02 PM)

After market: 3.75 0 (0%)

3.75

-0.22 (-5.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)03-05 2025-03-05/amc
Inst Owners43.73%
Inst Owner Change-94.43%
Ins Owners3.43%
Ins Owner Change3.55%
Market Cap559.05M
Analysts85
Price Target5.2 (38.67%)
Short Float %7.45%
Short Ratio6.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.87%
Min EPS beat(2)-19.83%
Max EPS beat(2)8.09%
EPS beat(4)1
Avg EPS beat(4)-7.35%
Min EPS beat(4)-19.83%
Max EPS beat(4)8.09%
EPS beat(8)4
Avg EPS beat(8)6.8%
EPS beat(12)7
Avg EPS beat(12)1.09%
EPS beat(16)8
Avg EPS beat(16)-0.96%
Revenue beat(2)2
Avg Revenue beat(2)3.15%
Min Revenue beat(2)2.86%
Max Revenue beat(2)3.44%
Revenue beat(4)2
Avg Revenue beat(4)0.38%
Min Revenue beat(4)-4.72%
Max Revenue beat(4)3.44%
Revenue beat(8)6
Avg Revenue beat(8)4.28%
Revenue beat(12)8
Avg Revenue beat(12)2.87%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)6.99%
PT rev (3m)9.28%
EPS NQ rev (1m)9.53%
EPS NQ rev (3m)17.4%
EPS NY rev (1m)0.82%
EPS NY rev (3m)-1.67%
Revenue NQ rev (1m)2.4%
Revenue NQ rev (3m)13.64%
Revenue NY rev (1m)0.38%
Revenue NY rev (3m)3.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.98
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS1.26
BVpS-0.19
TBVpS-1.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.66%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.36%
FCFM N/A
ROA(3y)-29.03%
ROA(5y)-51.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.89%
GM growth 5Y-2.98%
F-Score3
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.45%
Cap/Sales 0.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.79
Quick Ratio 1.29
Altman-Z -1.56
F-Score3
WACC11.29%
ROIC/WACCN/A
Cap/Depr(3y)26.86%
Cap/Depr(5y)41.84%
Cap/Sales(3y)1.35%
Cap/Sales(5y)9.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.22%
EPS Next Y8.2%
EPS Next 2Y23.14%
EPS Next 3Y28.69%
EPS Next 5Y27.94%
Revenue 1Y (TTM)22.72%
Revenue growth 3Y100.29%
Revenue growth 5Y130.85%
Sales Q2Q%12.31%
Revenue Next Year23.63%
Revenue Next 2Y21.44%
Revenue Next 3Y20.74%
Revenue Next 5Y20.36%
EBIT growth 1Y8.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.97%
EBIT Next 3Y44.54%
EBIT Next 5YN/A
FCF growth 1Y72.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.79%
OCF growth 3YN/A
OCF growth 5YN/A